KR20220047208A - 비소세포 폐암을 갖는 여성 비흡연자의 치료 방법 - Google Patents

비소세포 폐암을 갖는 여성 비흡연자의 치료 방법 Download PDF

Info

Publication number
KR20220047208A
KR20220047208A KR1020217031523A KR20217031523A KR20220047208A KR 20220047208 A KR20220047208 A KR 20220047208A KR 1020217031523 A KR1020217031523 A KR 1020217031523A KR 20217031523 A KR20217031523 A KR 20217031523A KR 20220047208 A KR20220047208 A KR 20220047208A
Authority
KR
South Korea
Prior art keywords
lung cancer
small cell
cell lung
patient
dithio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217031523A
Other languages
English (en)
Korean (ko)
Inventor
아디트야 쿨카미
아룬 아사이탐비
Original Assignee
랜턴 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 랜턴 파마 인코포레이티드 filed Critical 랜턴 파마 인코포레이티드
Publication of KR20220047208A publication Critical patent/KR20220047208A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
KR1020217031523A 2019-03-08 2020-03-08 비소세포 폐암을 갖는 여성 비흡연자의 치료 방법 Ceased KR20220047208A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815762P 2019-03-08 2019-03-08
US62/815,762 2019-03-08
PCT/US2020/021615 WO2020185640A1 (en) 2019-03-08 2020-03-08 Method for treating female non-smokers with non-small cell lung cancer

Publications (1)

Publication Number Publication Date
KR20220047208A true KR20220047208A (ko) 2022-04-15

Family

ID=72427123

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217031523A Ceased KR20220047208A (ko) 2019-03-08 2020-03-08 비소세포 폐암을 갖는 여성 비흡연자의 치료 방법

Country Status (11)

Country Link
US (1) US20220168258A1 (https=)
EP (1) EP3935043A4 (https=)
JP (2) JP2022525040A (https=)
KR (1) KR20220047208A (https=)
CN (2) CN113906010A (https=)
AU (2) AU2020235823A1 (https=)
BR (1) BR112021017716A2 (https=)
CA (1) CA3132827A1 (https=)
MX (1) MX2021010745A (https=)
SG (1) SG11202109705YA (https=)
WO (1) WO2020185640A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008352597B2 (en) * 2008-03-14 2012-03-08 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
JP5667886B2 (ja) * 2008-03-14 2015-02-12 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 癌患者の生存時間を増大させるための組成物及び化合物の使用方法
CA2717915A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
US20170007561A1 (en) * 2014-08-08 2017-01-12 Bionumerik Pharmaceuticals, Inc. Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur-containing, amino acid-specific small molecules

Also Published As

Publication number Publication date
JP2022525040A (ja) 2022-05-11
EP3935043A4 (en) 2023-01-11
JP2025081338A (ja) 2025-05-27
BR112021017716A2 (pt) 2021-11-16
MX2021010745A (es) 2021-12-15
US20220168258A1 (en) 2022-06-02
EP3935043A1 (en) 2022-01-12
AU2020235823A1 (en) 2021-11-04
WO2020185640A1 (en) 2020-09-17
AU2025267367A1 (en) 2025-12-04
CN120078760A (zh) 2025-06-03
SG11202109705YA (en) 2021-10-28
CA3132827A1 (en) 2020-09-17
CN113906010A (zh) 2022-01-07

Similar Documents

Publication Publication Date Title
Hainsworth et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens
Treat et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer
LoRusso et al. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors
JP2019521971A (ja) がんの処置
Gebbia et al. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the GOIM (Gruppo Oncologico Italia Meridionale)
US9155761B2 (en) Method for the treatment of cancer
CA3134156C (en) Chiauranib for treatment of small cell lung cancer
KR20220047208A (ko) 비소세포 폐암을 갖는 여성 비흡연자의 치료 방법
Weiss et al. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non–Small Cell Lung Cancer
EP2560648A2 (en) Method for treating pancreatic cancer
US20210379095A1 (en) Methods and Combination Therapy to Treat Biliary Tract Cancer
Tanaka et al. Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003)
US20130090320A1 (en) Method of treating prostate cancer
WO2023056063A1 (en) Raf kinase inhibitors for treating tumors harboring gene fusions
KR20120104594A (ko) 췌장암의 치료 방법
TW202337897A (zh) 抗ｐｄ－１抗體和抗ｖｅｇｆ－ａ抗體的藥物組合及其使用方法
Gent et al. An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin
WO2015171973A9 (en) Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitory compound based on chemosensitive status
WO2025137692A1 (en) Combination of dimesna and pemetrexed to treat non-small cell lung cancer (nsclc)
US20230172872A1 (en) Use of an rxr agonist and taxanes in treating her2+ cancers
Wachters et al. Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC
JP2013510126A (ja) コリン含有医薬組成物
JP2026509374A (ja) 腫瘍学的病態および神経障害性疼痛の処置における使用のための２－ヒドロキシ－オクタデセン－９－ｃｉｓ－オエート
Patel et al. Lung cancer: Advances in clinical research
Ross Lung Tumorigenesis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601